Triple Combination
Showing 1 - 25 of >10,000
Primary Condition: Advanced Tumors Trial in Guangzhou (JS009 as a monotherapy and JS009 as a Triple Combination Therapy in
Not yet recruiting
- Primary Condition: Advanced Tumors
- JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006
-
Blacktown, New South Wales, Australia
- +3 more
Feb 1, 2023
Real-world, 52-week Prospective Study to Capture Reasons for
Not yet recruiting
- Pulmonary Disease, Chronic Obstructive (COPD)
- Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler
- (no location specified)
Jun 13, 2023
C.Surgical Procedure; Gastrointestinal Trial in Guangzhou (palonosteron, dexamethasone, and fosaprepitant dissolved in 0.9%
Completed
- C.Surgical Procedure; Gastrointestinal
- palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl
- palonosetron, dexamethasone, and 0.9% NaCl
-
Guangzhou, Guangdong, ChinaThe Sixth Affiliated Hospital of Sun Yat-sen University
Dec 26, 2022
Melasma Trial in Los Angeles, Dallas (Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%)
Completed
- Melasma
- Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
-
Los Angeles, California
- +1 more
Jul 28, 2022
SARS-CoV Infection, Covid19 Trial in New Brunswick (Nitazoxanide, Placebo Nitazoxanide, Ribavirin)
Terminated
- SARS-CoV Infection
- Covid19
- Nitazoxanide
- +5 more
-
New Brunswick, New JerseyRobert Wood Johnson Medical School
May 3, 2022
ivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs
Not yet recruiting
- COPD
-
Budapest, HungaryNational Korányi Institute of Pulmonology
Feb 15, 2023
TNBC - Triple-Negative Breast Cancer Trial (Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy)
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- Camrelizumab Plus Chemotherapy and Famitinib
- Camrelizumab Plus Chemotherapy
- (no location specified)
Aug 17, 2023
HIV-infected Patients Switching to Long Acting Dual Therapy
Not yet recruiting
- HIV-1-infection
- (no location specified)
Jun 24, 2022
Triple-negative Breast Cancer Trial (Taxane and Carboplatin, Short-term Sintilimab, Surgery)
Not yet recruiting
- Triple-negative Breast Cancer
- Taxane and Carboplatin
- +2 more
- (no location specified)
Apr 25, 2023
Breast Cancer, Chemo Effect Trial in Beijing (Chidamide)
Recruiting
- Breast Cancer
- Chemotherapy Effect
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Feb 17, 2023
Metastatic Triple-Negative Breast Carcinoma, Breast Cancer Trial in Dallas (Neratinib Oral Tablet, Ruxolitinib Oral Tablet)
Not yet recruiting
- Metastatic Triple-Negative Breast Carcinoma
- Breast Cancer
- Neratinib Oral Tablet
- Ruxolitinib Oral Tablet
-
Dallas, TexasBaylor University Medical Center, Baylor Charles A Sammons Cance
Aug 22, 2023
Helicobacter Pylori Infection Trial in Medan (Esomeprazole, Lansoprazole, Amoxicillin)
Completed
- Helicobacter Pylori Infection
- Esomeprazole
- +3 more
-
Medan, North Sumatera, Indonesia
- +1 more
May 16, 2023
Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior
Active, not recruiting
- Cystic Fibrosis
- Elexacaftor / Ivacaftor / Tezacaftor
-
Nottingham, Nottinghamshire, United KingdomQueen's Medical Centre
Jan 24, 2023
Breast Cancer Trial in Beijing (Pembrolizumab, Paclitaxel, Epirubicin)
Recruiting
- Breast Cancer
- Pembrolizumab
- +3 more
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Dec 28, 2022
Triple Negative Breast Cancer Trial (Ociperlimab, Tislelizumab, Paclitaxel)
Not yet recruiting
- Triple Negative Breast Cancer
- Ociperlimab
- +7 more
- (no location specified)
Mar 30, 2023
Double Hit Lymphoma, Triple Hit Lymphoma Trial in Hangzhou (Selinexor+RCHOP)
Recruiting
- Double Hit Lymphoma
- Triple Hit Lymphoma
-
Hangzhou, Zhenjiang, ChinaZhejiang Cancer Hospital
Aug 2, 2023
Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure Trial (Control diet (ARM A) or Fasting-Like Approach (FLA, ARM
Not yet recruiting
- Breast Cancer
- +3 more
- Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)
- (no location specified)
Feb 28, 2023
HER2-positive Advanced Gastric Cancer Trial (trastuzumab, bevacizumab with paclitaxel (triple combination))
Not yet recruiting
- HER2-positive Advanced Gastric Cancer
- trastuzumab, bevacizumab with paclitaxel (triple combination)
- (no location specified)
Dec 6, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Not yet recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +3 more
- Biopsy
- +4 more
- (no location specified)
Jan 4, 2023
Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma Trial in Tampa (Talimogene laherparepvec, Paclitaxel)
Active, not recruiting
- Breast Cancer
- +3 more
- Talimogene laherparepvec
- Paclitaxel
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Nov 10, 2022
Metastatic Triple-negative Breast Cancer Trial in Wuhan (Surufatinib, Tislelizumab)
Not yet recruiting
- Metastatic Triple-negative Breast Cancer
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Feb 27, 2023
Uncomplicated Plasmodium Falciparum Malaria Trial in Bagamoyo (Artemether-lumefantrine and Amodiaquine Drug Combination,
Not yet recruiting
- Uncomplicated Plasmodium Falciparum Malaria
- Artemether-lumefantrine and Amodiaquine Drug Combination
- +2 more
-
Bagamoyo, Dar esSalaam, Tanzania
- +1 more
Feb 28, 2023
Triple Negative Breast Cancer Trial in Beijing (SHR-1210 + Apatinib +Fluzoparib)
Completed
- Triple Negative Breast Cancer
- SHR-1210 + Apatinib +Fluzoparib
-
Beijing, Beijing, ChinaBeijing Cancer Hosptial
Aug 9, 2022
Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma Trial in United
Recruiting
- Relapsed Chronic Lymphocytic Leukemia
- +4 more
-
Phoenix, Arizona
- +7 more
Apr 28, 2022